News >

NETs Treatment Arsenal Expands, With More Progress on the Horizon

Brandon Scalea
Published: Wednesday, May 01, 2019

Lowell B. Anthony, MD, FACP

Lowell B. Anthony, MD, FACP

The addition of everolimus (Afinitor) and telotristat ethyl (Xermelo), to the treatment arsenals in neuroendocrine tumors (NETs) and carcinoid syndrome, respectively, is helping to achieve disease control and manage adverse events (AEs), said Lowell B. Anthony, MD, FACP, and several emerging therapies have the potential to push the envelope even further.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication